Forest Laboratories, Inc.
http://www.frx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Forest Laboratories, Inc.
Pharma Execs Jumping Onboard Private Equity Train
More C-Suite level pharma executives are lending their domain expertise to private equity firms, which then use their skills for commercial due diligence on targets or in an operating partner role in portfolio companies once a deal is sealed. PEs are also increasingly opting for control deals, at least in India, with an aim to run the acquired firm professionally thereon.
Reimbursement Dispute Between Novitas And iRhythm Hits An Impasse
Local Medicare carrier Novitas raised its reimbursement rates for continuous cardiac monitoring, but iRhythm has concluded the rates are still too low and is preparing to discontinue serving this Medicare segment.
Roche Shelves Phase III Huntington's Candidate Tominersen
Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.
Stockwatch: Should A Biotech’s First Product Be Out-Licensed Or Self-Marketed?
The licensing or self-commercialization decision can be important for the success of a biotech company, but do other more fundamental factors concerning the drug dictate a company’s success?
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Aptalis Pharma Inc. (Axcan Pharma, Inc.
- Eurand N.V.
- Mpex Pharmaceuticals, Inc.)
- Cerexa, Inc.
- Clinical Data, Inc.